Privately-held French company Orphelia Pharma, which is focused on pediatric and orphan medicines, has filed a centralized Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Kizfizo, the first oral liquid formulation of temozolomide, the active ingredient of Merck & Co’s (NYSE: MRK) Temodar.
Kizfizo, known as Ped-TMZ or Kimozo during its clinical development and ongoing early access programs, is designed specifically for use in the treatment of children with relapsed or refractory neuroblasto+ma, oncology indications with a very poor prognosis. This oral suspension, which is taste-masked, was developed for children: it allows a precise dose to be administered orally or via a nasogastric tube in a small volume.
Orphelia Pharma has been developing Kizfizo in collaboration with Gustave Roussy, the leading European cancer center, for the last six years. It has an agreement with Tanner Pharma to manage the supply and distribution of the drug.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze